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The simian immunodeficiency virus (SIV) macaque model system has been used extensively to study AIDS pathogenesis
and to test candidate vaccines for their ability to protect against homologous or heterologous challenge with pathogenic SIV
or SHIV. Recent studies suggest that stimulation of HIV-1-specific CTL responses is important for effective vaccination
against HIV-1. While quantitative measurements of SIV-specific cytotoxic T lymphocyte (CTL) responses have been facilitated
by the use of tetrameric peptide complexes, this technique is currently limited to the study of Mamu-A*01-positive rhesus
macaques. Furthermore, very few SIV-specific CTL epitopes have been identified, and there is limited identification of other
MHC alleles in macaques. In this study, cytokine flow cytometry (CFC) was used to quantify SIV-specific CD81 antigen-
reactive T cells in macaques infected with SIV. We found a strong correlation (r 5 0.96, P , 0.001) between CD81
antigen-reactive T cells stained with the Mamu-A*01 p11C, C-M tetramer and production of intracellular TNF-a in the CFC
assay. Furthermore, the CFC assay was used to identify a novel SIV-specific CTL epitope in Envelope (SIV Env, a.a. 486–494,
sequence AEVAELYRL). The use of the CFC assay facilitates the study of antigen-reactive T cell responses in SIV infection
and vaccination. © 2000 Academic Press
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Recent studies have highlighted the critical role that
cellular immune responses may play in protection
against infection with HIV-1 (Akridge et al., 1999; Bernard
et al., 1999; Cheynier et al., 1992; De Maria et al., 1994;
owke et al., 1996; Rowland-Jones et al., 1993, 1995), and
stimulation of virus-specific cellular responses have be-
come a priority in HIV-1 vaccine strategies (Letvin, 1998).
The simian immunodeficiency virus (SIV) challenge-pro-
tection model has been extensively used to test and
compare experimental vaccines, and in some cases,
protection against pathogenic SIV challenge has been
documented in the apparent absence of neutralizing an-
tibodies (Lehner et al., 1998; Nilsson et al., 1998; Robin-
son et al., 1999). However, comparative quantification of
SIV-specific CTL responses elicited by these vaccines
has been difficult, principally due to the laborious nature
of limiting dilution analysis.
The use of tetrameric MHC peptide complex technol-
ogy has provided a new methodology to rapidly identify
and quantify antigen-reactive T cells (Altman et al., 1996;
Kuroda et al., 1998; Ogg et al., 1998, 1999). A tetrameric
peptide complex of the Mamu-A*01-restricted CTLC
s
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347epitope in SIV Gag, p11C, C-M (Allen et al., 1998; Hanke
et al., 1999; Miller et al., 1991) has been used to measure
he kinetics of SIV Gag p11C, C-M-specific CTL in pri-
ary SIV infection (Kuroda et al., 1999b), in vaccinated
nimals (Seth et al., 1998) and in lymphoid tissues (Jor-
an et al., 1999; Kuroda et al., 1999a). While this tech-
ique has provided a major advance in the identification
f antigen-reactive T cell responses in Mamu-A*01-pos-
tive monkeys, it is currently limited because few SIV-
pecific CTL epitopes have been identified and other
HC alleles in macaques have not been fully character-
zed or expressed (Vogel et al., 1999). In addition, tet-
amer staining provides no measure of effector function
lysis or cytokine secretion) of the antigen-reactive
D81 T cells.
Virus-specific CTL can mediate effector functions
hrough perforin- or Fas-mediated lysis of infected target
ells or by release of cytokines such as IFN-g and TNF-a.
An alternative method to quantify virus-specific T cells is
to detect intracellular cytokines produced after antigen-
specific stimulation (Kern et al., 1998; Murali-Krishna et
al., 1998). In this study, we have used a cytokine flow
cytometry (CFC) assay to measure the production of
TNF-a in SIV-specific CD81 T cells. We compared the
uantification of Mamu-A*01-restricted SIV Gag p11C,
-M-reactive T cells using tetrameric-peptide complex
taining and CFC, and showed a strong positive corre-
0042-6822/00 $35.00
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348 DONAHOE ET AL.lation between these two assays. We also demonstrated
that the CFC assay can be used to identify novel SIV-
specific CTL epitopes using SIV-derived peptides, which
will be of value in the assessment of candidate SIV
vaccines.
RESULTS
Enumeration of SIV Gag p11C, C-M epitope-specific
responses by detection of intracellular TNF-a
Quantification of SIV-specific CTL epitopes through
limiting dilution assays is technically difficult and re-
quires the prior generation of autologous BCL. We
sought to simplify the procedure by measuring the pro-
duction of intracellular cytokines from CD81 T cells in
response to specific antigenic stimulation. As a positive
control for cytokine production, we incubated PBMC from
an SIV-infected Mamu-A*01-positive monkey (Rh 1484)
with the superantigen Staphylococcus enterotoxin B
SEB). Direct staining of PBMC showed TNF-a produced
rom 16.59% of CD81 T cells in response to SEB stimu-
ation (Fig. 1A). CD81 T cells responsive to the SIV Gag
11C, C-M epitope were then enumerated after direct
eptide stimulation with the p11C, C-M peptide in vitro. It
as found that 1.31% of CD81 T cells upregulated CD69
nd produced intracellular TNF-a in response to peptide
timulation (Fig. 1B). Background release of TNF-a was
0.19% (Fig. 1C). The reproducibility of the assay was
FIG. 1. Specific antigenic stimulation with peptide p11C, C-M induces
was measured in the CFC assay from a Mamu-A*01 1ve SIV-infecte
TNF-a-secreting cells is shown top right in each panel. Stimulation wi
produced minimal TNF-a (C). Stimulation with peptide p11C, C-M indu
20-mer overlapping peptides from SIV Gag (Table 1), including a 20-mer
epitope peptide was added to Pool 1 (D). Another pool, Pool 2, contai
negative control (F).tested by comparing the production of cytokine from
multiple aliquots of PBMC samples from two macaques.The standard deviation of responses were 0.09 and 0.3%,
respectively. IFN-g was also produced on peptide spe-
ific stimulation of CD81 cells and correlated with pro-
uction of TNF-a (correlation coefficient r 5 0.998; data
ot shown). No TNF-a was produced in CD3-CD81 cells
n response to peptide stimulation (data not shown). The
pecificity of the CFC assay was confirmed using PBMC
rom an SIV-uninfected Mamu-A*01-positive macaque
T-80. Only background levels of TNF-a were produced
(data not shown).
Because the quantity of PBMC obtained from a single
bleed of a rhesus macaque is often limited, it would be
advantageous to screen pools of peptides in the CFC
assay to identify novel peptide epitopes. We made a pool
of SIV Gag peptides (Pool 1, which contained the p11C,
C-M epitope encoded within a 20-mer peptide, as well as
four other 20-mer Gag peptides; Table 1) and compared
cytokine production after stimulation with either the pool
or individual peptides. Three conditions were then com-
pared: Pool 1 alone, Pool 1 plus the addition of the
minimal peptide p11C, C-M, and Pool 2 which contained
five Gag 20-mer peptides not recognized in the CFC
assay (Table 1). Direct measurement of TNF-a release in
he CFC assay showed 0.74% CD81 T cells produced
NF-a after stimulation with pool 1 (Fig. 1E) compared to
.31% for the minimal peptide alone. When the p11C, C-M
eptide was added to Pool 1, the percentage of TNF-a
produced increased to 1.01% (Fig. 1D) but was still lower
production from CD81 CD691 T cells. Intracellular TNF-a production
aque. Cells were stained with anti-CD8. The percentage of CD691
uperantigen SEB induces production of TNF-a (A). Unstimulated cells
F-a production in the SIV-infected macaque (B). Pool 1 contained five
e which encompassed the minimal epitope p11C, C-M (E). The minimal
other five 20-mer overlapping Gag peptides (Table 1), was used as aTNF-a
d mac
th the s
ced TN
peptidthan the optimal peptide (Fig. 1B), suggesting some de-
gree of antigenic competition within the peptide pools.
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349SIV CTL EPITOPE IDENTIFICATION BY CYTOKINE STAININGPool 2 (Fig. 1F) had background levels of cytokine re-
lease. This demonstrates that peptide pools can be used
to screen for SIV CTL epitopes in the CFC assay.
Quantification of SIV p11C, C-M response with CFC
staining is comparable to staining with a Mamu-A*01
p11C, C-M tetrameric peptide complex
SIV Gag p11C, C-M-Mamu-A*01 tetrameric complexes
have been used to analyze CTL responses early after SIV
infection and localize antigen-reactive T cells to tissues
such as lymph node and semen (Kuroda et al., 1998,
999a,b). To compare the quantity of antigen-reactive T
ells measured by tetrameric peptide staining to that
easured by CFC, PBMC were stained by both methods
nd the results analyzed by FACS. The positive control
or the tetramer was a p11C, C-M-derived CTL line and
he negative control was a non-Mamu-A*0–1-positive
nimal (data not shown). On direct staining with tetramer,
.60% of CD81 T cells were p11C, C-M positive (Fig. 2A).
y comparison, 0.96% of PBMC produced TNF-a after
p11C, C-M stimulation as measured in the CFC assay
TABLE 1
SIV-Sequence Derived Peptides
Peptide or
pool Protein Peptide Amino acid sequence
ool 1 gag p26 714.1 PVQQIGGNYVHLPLSPRTLN
gag p26 714.2 HLPLSPRTLNAWVKLIEEKK
gag p26 714.3 AWVKLIEEKKFGAEVVPGFQ
gag p26 714.4 FGAEVVPGFQALSEGCTPYD
gag p26 714.5 ALSEGCTPYDINQMLNCVGD
11C, C-M gag p26 9-mer CTPYDINQM
ool 2 gag p26 714.18 RAEQTDAAVKNWMTQTLLIQ
gag p26 714.19 NWMTQTLLIQNANPDCKLVL
gag p26 714.20 NANPDCKLVLKGLGVNPTLE
gag p26 714.21 KGLGVNPTLEEMLTACQGVG
gag p26 714.22 EMLTACQGVGGPGQKARL
ool 3 env gp120 774.46 WTDGNQTNITMSAEVAELYR
env gp120 774.47 MSAEVAELYRLELGDYKLVE
env gp120 774.48 LELGDYKLVEITPIGLAPTD
env gp120 774.49 ITPIGLAPTDVKRYTTGGTS
30 env gp120 9-mer SAEVAELYR
31 env gp120 9-mer AEVAELYRL
32 env gp120 9-mer EVAELYRLE
ool 4 gag p26 714.1 PVQQIGGNYVHLPLSPRTLN
gag p26 714.2 HLPLSPRTLNAWVKLIEEKK
gag p26 714.3 AWVKLIEEKKFGAEVVPGFQ
gag p26 714.4 FGAEVVPGFQALSEGCTPYD
gag p26 714.6 INQMLNCVGDHQAAMQIIRD
5 gag p26 714.5 ALSEGCTPYDINQMLNCVGD
ool 5 env gp120 774.44 PREGDLTCNSTVTSLIANID
env gp120 774.45 TVTSLIANIDWTDGNQTNIT
env gp120 774.46 WTDGNQTNITMSAEVAELYR
env gp120 774.48 LELGDYKLVEITPIGLAPTD
env gp120 774.49 ITPIGLAPTDVKRYTTGGTS
47 env gp120 774.47 MSAEVAELYRLELGDYKLVE(Fig 2B). A comparison between tetramer and CFC stain-
ing using PBMC samples obtained over a 2-year timecourse from Animal Rh 1484 showed a strong positive
correlation (r 5 0.96; P , 0.001; Fig. 2C).
The CFC assay can be used to detect specific
antigen-reactive cells after in vitro culture
A period of in vitro stimulation with antigen has been
shown to increase the percentage of tetramer positive
cells within a bulk PBMC culture (19). We stimulated
PBMC for 14 days in vitro with fixed autologous BCL
infected with rVV-Gag and then stained either with the
Mamu-A*01/p11C, C-M tetramer or measured TNF-a pro-
uction in the CFC assay. Comparable numbers of CD81
11C, C-M-specific T cells were detected by tetramer
taining (24.4%) and TNF-a production (21.87%; Figs. 3A
nd 3B). To test the function of the CTL, bulk culture cells
ere also tested in a standard 51Cr-release assay
gainst autologous or mismatched target cells infected
ith a recombinant vaccinia virus expressing SIV Gag or
ulsed with the p11C, C-M peptide. A high degree of
pecific lysis against the p11C, C-M peptide and SIV
ag-rVV was observed (Fig. 3C), indicating that the an-
igen reactive cytokine producing cells detected in the
FC assay had lytic potential after restimulation in vitro.
dentification of a novel SIV-specific CTL epitope in
nv using the CFC assay
We identified an SIV Env-specific CTL response in
acaque Rh 1488, immunized with SIVDnef mac239 (Fig.
). To identify which peptide was recognized, we tested
ools of overlapping SIV Env peptides as antigenic stim-
lants in the CFC assay. One pool, Pool 3, showed a
ositive result using CFC. Staining was repeated with
ndividual peptides within Pool 3, and one peptide, p47,
sequence MSAEVAELYRLELGDYKLVE) stimulated
NF-a production (data not shown). We confirmed rec-
gnition of this peptide using a 51Cr release assay. A
panel of overlapping 9-mer peptides was then used to
map the epitope, and the 9-amino-acid peptide p31 (se-
quence AEVAELYRL) was identified as the 9-mer peptide
recognized, by the CFC assay (Fig. 4D) and by sensiti-
zation of target cells in a 51Cr release assay (data not
hown). Peptides 30 and 32, which overlapped the p31
eptide by one amino acid (see Table 1), failed to sen-
itize targets or stimulate the production of TNF-a (Figs.
4C and 4E). Preliminary assessment of MHC restriction
of this response shows that this peptide is not presented
by Mamu-A*01 or B*02 (data not shown).
Different concentrations of the optimal peptide Env
p31 were used to stimulate the production of cytokine
(Fig 5A). For this optimal peptide, a concentration of 1 or
0.1 mM stimulated over 1.3% cytokine production. With
reduction in peptide concentration, less cytokine was
produced with background levels seen at 0.1 nM peptide.
The optimal peptide was compared with the 20-mer
peptide (Env p47), and the minimal peptide (Env p31)
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350 DONAHOE ET AL.stimulated more cytokine production (Fig. 5B). This was
also seen with a comparison of the minimal peptide
p11C, C-M and a 20-mer in Rh 1484 (data not shown). A
low level of cytokine was detected from Peptide Pool 5
plus Env p47. No specific cytokine was detected with a
mixture of peptides, p5 1 p47 1 Pool 4 1 Pool 5 (Fig.
5B). The sensitivity of the assay was determined by
mixing peptide stimulated with unstimulated autologous
PBMC at various ratios. The sensitivity was around 1 in
5000, similar to that reported for the tetramer assay (Ogg
et al., 1998) (data not shown).
DISCUSSION
The SIV/macaque model system has been used ex-
tensively in the study of AIDS pathogenesis and to test
candidate vaccines for their ability to protect against
homologous or heterologous challenge with pathogenic
SIV or SHIV. Recent studies have suggested that stimu-
lation of HIV-1-specific CTL responses is important for
vaccination against HIV-1, and several candidate vac-
FIG. 2. Comparison of quantitation of SIV Gag p11C, C-M-specific CD
of PBMC with Mamu-A*01/p11C, C-M tetramer. The percentage of tetra
C-M stimulated TNF-a production (B). Correlation between tetramer s
ssays. The correlation coefficient between tetramer staining and TNFcines tested in primates have elicited protection against
challenge without stimulation of neutralizing antibodies
u
s(Lehner et al., 1998; Nilsson et al., 1998; Robinson et al.,
1999). While quantitative measurements of SIV-specific
CTL responses have been facilitated by the use of tet-
rameric MHC peptide complexes, this technique is cur-
rently limited to the study of Mamu-A*01-positive rhesus
macaques. Furthermore, very few SIV-specific CTL
epitopes have been identified, and there is limited iden-
tification of other MHC alleles in macaques. In this study,
we used cytokine flow cytometry (CFC) to quantify SIV-
specific antigen-reactive CD81 T cells in SIV-infected
macaques. We found a strong correlation between stain-
ing with the Mamu-A*01/p11C, C-M tetramer and produc-
tion of intracellular TNF-a. Furthermore, the CFC assay
as used to identify a novel SIV-specific CTL epitope in
he SIV Envelope protein. Identification of new epitopes
ill increase the usefulness of the macaque model in the
valuation of CTL epitope vaccines.
Quantification of antigen-reactive T cells following SIV
nfection or vaccination is essential in the investigation of
he correlates of protection against SIV challenge and
cell responses using tetramer staining and CFC assay. Direct staining
sitive CD81 T cells is shown in the top right corner (A). Peptide p11C,
and CFC assay (C). Aliquots of PBMC were split and tested in both
duction in the CFC assay (r) was 0.96, and P , 0.001.81 T
mer-ponderstanding the role of CTL responses in pathogene-
is of SIV-induced disease. Until recently, measurements
e
(
a
351SIV CTL EPITOPE IDENTIFICATION BY CYTOKINE STAININGFIG. 3. Quantitative correlation between tetramer staining and CFC assay on in vitro expanded p11C, C-M-specific CTL. Bulk cultures were
stablished as described (Materials and Methods) and tested either with tetramer staining (A) or CFC assay (B). Cells were tested against autologous
1484) or mismatched (1488) BCL, infected with SIV gag rVV, or vaccinia control, TK2, without peptide (unpulsed) or pulsed with peptide p11C, C-M
t 10 mg/ml.FIG. 4. Identification of a novel SIV Env CTL epitope using the CFC assay. Intracellular TNF-a production was measured in the CFC assay on PBMC
from Animal Rh 1488. Stimulation with the superantigen SEB is shown in (A). Unstimulated cells made low amounts of TNF-a (B). SIV Env peptide p31
stimulated TNF-a production (D). SIV Env peptides p30 and p32 had background levels of TNF-a production (C and E).
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352 DONAHOE ET AL.of the numbers of virus-specific CD81 T cells following
nfection or after vaccination have been derived from
imiting dilution analysis (LDA), a method that is ex-
remely tedious, technically demanding, and notoriously
ariable (Doherty, 1998). Three new methods have shown
hat the LDA assay greatly underestimates the number of
ntigen-reactive T cells in viral infection. The first method
dentified antigen-specific T cells through use of MHC
eptide tetrameric complexes (Altman et al., 1996) and
showed that following a virus infection, the number of
virus-specific T cells was greater than previously thought
(Kuroda et al., 1999a; Murali-Krishna et al., 1998; Ogg et
al., 1998). The other two methods detect the production
of cytokine after stimulation with viral antigen, either in
an ELISPOT assay (Butz and Bevan, 1998; Lalvani et al.,
1997; Larsson et al., 1999; Murali-Krishna et al., 1998;
Spiegel et al., 1999) or by staining cytoplasmic cytokine
in fixed cells after stimulating for 6 h in the presence of
Brefeldin A (Kern et al., 1998; Murali-Krishna et al., 1998).
In one study of Epstein–Barr virus (EBV)-specific T cells
in chronic EBV infection, a comparison between these
methods showed the number of virus-specific T cells
measured by ELISPOT were 5.3 times higher than that
obtained from LDA, but were slightly less than the fre-
quency measured by tetramer (Tan et al., 1999).
The number of studies that quantified SIV-specific T
cell responses before the advent of tetramer technology
are limited due to the prolonged tissue culture and re-
agents required for an SIV-specific CTL limiting dilution
assay. Tetramers have now been constructed with the
Mamu-A*01 allele and used to study the frequency of
antigen-reactive T cells in SIV-infected or vaccinated
macaques (Hanke et al., 1999; Jordan et al., 1999; Kuroda
FIG. 5. The magnitude of TNF-a production is dependent upon pepti
he CFC assay on PBMC from Animal Rh 1488 with peptide Env p31 at
f different length or mixtures was compared (B). Peptides were the op
inimal epitope, a mixture of six 20-mer env peptides, and also with tet al., 1999a,b; Seth et al., 1998). However, this method is
limited in two important respects: the requirement forprior identification of the minimal peptide epitope region,
and the expression of the MHC allele of interest. It is now
considered essential to stimulate virus-specific CTL as
part of an effective HIV vaccine (Letvin, 1998), and there
is urgent need to make comparisons in the quantity of
antigen-reactive T cells elicited by candidate vaccines.
We therefore sought to develop a novel method that
would allow the direct measurement of SIV-specific
CD81 T cells. Such an assay could be used to quantify
antigen-reactive T cells following infection or vaccination
and to identify new epitope regions for use in the man-
ufacture and testing of epitope-based vaccines (Hanke
et al., 1999).
The detection of intracellular cytokine production from
human antigen-reactive T cells has been used to mea-
sure cytokines released from CMV-specific CD41 T cells
(Komanduri et al., 1998; Pitcher et al., 1999; Waldrop et al.,
1997), and CMV-specific CD81 T cells (Kern et al., 1998).
In the present study, we measured SIV-specific CD81
antigen-reactive T-cell responses by detection of TNF-a
production from CD81 T cells after specific peptide
stimulation. Antigen-reactive CD81 T cells produce a
umber of cytokines after antigenic stimulation, includ-
ng TNF-a, and we chose to measure the production of
NF-a because it is produced earliest after antigenic
timulation (Mascher et al., 1999). We also showed that
he production of IFN-g could be detected in this assay
nd that there was a strong correlation between the
esults obtained with the two cytokines.
The CFC assay identifies the number of CD81 anti-
en-reactive T cells that produce TNF-a after a specific
ntigenic stimulus. CD81 T cells (0.96%) in Animal
h1484 produced TNF-a after stimulation with SIV-Gag
entration and length. Intracellular TNF-a production was measured in
ilutions (A). The production of cytokine after stimulation with peptides
defined minimal epitope Env p31, a 20-mer Env p47 encompassing the
ition of six gag peptides (12 peptides from gag and env).de conc
log10 dpeptide p11C, C-M (Fig. 2B); this animal had been in-
fected with SIVmac239Dnef and protected against chal-
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353SIV CTL EPITOPE IDENTIFICATION BY CYTOKINE STAININGlenge with pathogenic SIV (Connor et al., 1998). Interest-
ingly, no plasma viremia was detected at the time point of
the PBMC sample used in the CFC assay (data not
shown). The maintenance of virus-specific CTL re-
sponses at high frequency despite undetectable viral
replication suggests that continuous antigenic stimula-
tion may not be necessary to maintain the effector pop-
ulation, although it is possible that low-level viral repli-
cation from virus sequestered in lymphoid tissues may
be stimulating these effector T cells. In some individuals
infected with an attenuated nef-deleted virus who have
undetectable plasma viremia (Dyer et al., 1999), HIV-1-
specific CTL can be detected at high frequency. The
mechanisms by which an effector CTL response can be
maintained at high frequency will be important to eluci-
date.
In addition to quantifying SIV-specific antigen-reactive
T cell responses, the identification of new SIV-specific
CTL epitopes is essential in understanding immune re-
sponses induced following vaccination and in response
to pathogenic SIV infection. Only a limited number of
SIV-specific-CTL epitopes have been identified thus far
(Allen and Watkins, 1998), and this method will be useful
for additional epitope identification, particularly using
pools of peptides to simplify viral epitope identification in
future vaccine studies. From our data, the use of optimal
peptides appears preferable to longer peptides, although
longer peptides used at high concentration may still be
useful for screening purposes. In addition, the number of
peptides in a peptide pool should be kept to a minimum
as we saw a loss of sensitivity when peptide pools were
used compared to single peptides. As vaccine candi-
dates may stimulate SIV-specific CD81 T cells at low
frequency, the use of rVV restimulated cultures to identify
responses should be considered (Fig. 3B).
Recent evidence suggests that under certain circum-
stances CD81 antigen-reactive T cells may fail to mount
effector functions, including cytokine release (Lee et al.,
1999; Zajac et al., 1998). In this study, we show that the
population of PBMC stained with tetramer is slightly
higher than that identified by CFC but indicates that most
of the tetramer-positive cells are probably able to secrete
cytokine. The combination of intracellular cytokine stain-
ing and tetramer analysis will assist in identifying
whether such immunosilent T cells are present in SIV-
infected animals with low CD41 T cells.
In conclusion, the main use of this intracellular cyto-
kine flow cytometry staining technique will be in the
quantitative assessment of SIV-vaccine candidates and
identification of novel dominant and nondominant viral
epitopes. Stimulation of a vigorous CTL response will
play a role in the development of an HIV-1 vaccine. This
method will allow comparison of CTL immunogenicity
and effector function in the primate model.
1
wMATERIALS AND METHODS
Animals. Female rhesus macaques (Macaca mulatta)
were housed either at the Laboratory for Experimental
Medicine and Surgery in Primates, Tuxedo, NY, or at the
Tulane Regional Primate Research Center, Covington,
LA. Animals were maintained in accordance with the
guidelines of the local institutional animal use commit-
tee. Animals were infected intravenously with 2 3 104
TCID50 SIVmac239Dnef and challenged with 10 animal
infectious doses (AID) of uncloned SIVmac251 (kindly
provided by Dr. R. Desrosiers) using the same route 10
weeks later (Connor et al., 1998). Control animals were
uninfected with SIV. Rhesus monkeys were screened for
the presence of the Mamu-A*01 allele by a PCR-based
technique (Dr. D. Watkins, Wisconsin Regional Primate
Center) (Evans et al., 1997).
Cell lines. Autologous B-lymphoblastoid cell lines
(BCL) from study animals were transformed by incubat-
ing peripheral blood mononuclear cells (PBMC) at 37°C
with RPMI 1640 (Biowhittaker, Walkersville, MD) supple-
mented with R-15 (15% fetal calf serum (FCS), 10 mM
HEPES, 2 mM L-glutamine and 50 IU of Pen./Strep.) and
erpesvirus papio from the supernatant of S594 cell line
kindly provided by Dr. D. Watkins, Wisconsin Regional
rimate Center, Madison, WI). PBMC were isolated from
eparinized or EDTA blood by centrifugation over a Fi-
oll-sodium diatrizoate gradient (Phamacia, Uppsala,
weden).
Peptides. Peptides were provided by the MRC AIDS
irected Program (Potters Bar, UK) or the Endocrine Unit,
assachusetts General Hospital, MA, and are listed in
able 1. The p11C, C-M peptide was made in Oxford, UK
T.H.).
Stimulation of effector cells. Cryopreserved PBMC
ere thawed, washed twice in R-15, and resuspended at
3 106 cells/ml in R-15. For superantigenic stimulation,
BMC were incubated with staphylococcal enterotoxin B
SEB, Sigma, St. Louis, MO) at 5 mg/ml for 3 days,
ashed twice, and resuspended into R-15 plus 100 in-
ernational units (IU) human recombinant interleukin-2
R-15–100) (Kakimoto et al., 1999). For antigen-specific
timulation, autologous BCL were infected at a m.o.i. of 2
ith recombinant vaccinia virus expressing SIV gene
roducts Env, Gag, or control vaccinia (Therion Biologics,
ambridge, MA). Following overnight incubation, in-
ected BCL were separated on a Ficoll gradient, washed
wice with R-15, counted, and incubated with 1.5% (w/v)
araformaldehyde (Sigma, St. Louis, MO) in PBS (Bio-
hittaker, Walkersville, MD) at room temperature for 30
in. Cells were then pelleted and incubated with 0.2 M
lycine (Fisher, Fairlawn, NJ) in PBS at room temperature
or 15 min. After glycine incubation, cells were pelleted,
ashed and resuspended in filter-sterilized FCS (1 3
70 /ml), and stored at 4°C. PBMC were then cultured
ith stimulators at a responder to stimulator ratio of 1:1
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354 DONAHOE ET AL.in R-15, with R-15–100 added on the third day. CTL as-
says were performed 10–14 days after stimulation.
51Chromium-release assay. SIV-specific cytolytic activ-
ity was measured using a standard 51chromium-release
ssay with cold target inhibition and autologous recom-
inant vaccinia-infected BCL as targets (Johnson et al.,
997). Recombinant vaccinia viruses were rVV-Gag
vAbT252, encoding the SIVmac251 p55gag and protease
roteins), rVV-Env (vAbT2531 1126 Mg the SIVmac251
nvelope), or control (Vaccinia Thymidine kinase nega-
ive, TK2) (Therion Biologics, Cambridge, MA).
Tetramer staining. The soluble Mamu-A*01 p11 C, C-M
etramer was made as previously described (Hanke et
l., 1999). To quantify tetramer-reactive cells, cryopre-
erved PBMC were thawed and washed twice in R-15.
hycoerythrin (PE)-conjugated Mamu-A*01 p11C, C-M
etramer was added for 20 min at 37°C, and the suspen-
ion was then incubated with anti-CD8 TriColor (Caltag,
urlingame, CA, clone 3B5) for 30 min at 4°C. Cells were
ashed twice and fixed with 2% paraformaldehyde in
BS. PBMC were analyzed for the expression of cell
urface markers and tetramer-positive cells using a Flu-
rescent Activated Cell Sorter (FACS) Calibur (Becton-
ickinson, San Jose, CA) with CellQuest Software (Bec-
on-Dickinson, San Jose, CA). The mononuclear cell pop-
lation was gated on the basis of forward and side
cattering properties and subsequently evaluated for the
luorochromes conjugated to the tetramer and anti-CD8
ntibody. Staining of PBMC identified a distinct popula-
ion of CD8/tetramer double-positive cells. The tetramer
as used to stain a known SIV Gag p11C, C-M CTL line
s positive control, and the negative control was PBMC
rom an SIV-uninfected Mamu-A*01-positive animal.
Cytokine flow cytometry. To quantify cells which pro-
uce TNF-a, cryopreserved PBMC were thawed and
washed twice in R-15. Cells were resuspended in 200 ml
f R-15 and incubated with either staphylococcal Entero-
oxin B (SEB) (5 mg/ml) (Sigma), peptide (10 mg/ml), or
media for 6 h in a 96-well v-bottom microtiter plate (Nunc,
Roskilde, Denmark). The incubation was done at 37°C in
5% CO2 with the last 5 h performed in the presence of
refeldin A (10 mg/ml) (Sigma), a potent inhibitor of in-
racellular transport that prevents secretion of any pro-
uced cytokines. Antibody to CD28 (1 mg/well) (clone
293, Becton-Dickinson, San Jose, CA) was also added
uring the incubation to facilitate costimulation. After
timulation, the cells were washed in PBS, incubated for
0 min at 37°C in PBS10.02% EDTA, and again washed
n PBS. Cells were then briefly fixed in 4% paraformalde-
yde (Sigma) for 5 min at 37°C, washed in PBS11% BSA
1% BSA) (Sigma), and stored at 280°C in 1% BSA con-
aining 10% DMSO (Sigma). The next day, cells were
hawed and washed in 1% BSA. They were then sequen-
ially incubated for 10 min each in FACSLyse and
ACSPerm (Becton-Dickinson) solutions at room tempera-
ure and washed once in 1% BSA. Following permeabiliza-ion, cells were stained with monoclonal antibodies specific
or CD8 [conjugated to fluoroscein isothiocyanate (FITC),
ecton-Dickinson], intracellular TNF-a [conjugated to phy-
oerythrin (PE), clone 6401.111, No. 340512, Becton-Dickin-
on], IFN-g (conjugated to PE, Biosource Int’l, Camarillo,
CA, clone MD-1, part: AHC 4337), and CD69 [conjugated to
peridinin chlorophyll protein (PerCp), Becton-Dickinson]. Af-
ter staining, cells were washed twice and resuspended in
1% paraformaldehyde in PBS. Samples were collected by a
FACS Calibur flow cytometry instrument and analyzed us-
ing CellQuest software. Fifty thousand total events were
acquired for each sample with sequential gating of mono-
nuclear cells into the CD41 and CD81 subpopulations.
These T cell subsets were further evaluated for the expres-
sion of intracellular TNF-a or IFN-g and the early activation
marker, CD69.
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